|
|
Vaccine Detail
|
Mature dendritic cell melanoma vaccine |
| Vaccine Information |
- Vaccine Name: Mature dendritic cell melanoma vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: melanoma tumor-specific peptides (NCT03092453)
- Immunization Route: Other
- Description: Autologous mDC3 vaccine may elicit a cytotoxic T-cell (CTL) response against cancer cells. (NCIT_C162250) Autologous dendritic cells are pulsed with melanoma tumor-specific peptides. The mature dendritic cell (mDC3/8) vaccine (primer and booster) in patients with stage III and stage IV melanoma is followed by treatment with pembrolizumab (anti-PD-1 therapy). Using dendritic cells (a kind of white blood cell) as a vaccine could stimulate your own immune system to react to your melanoma cells.(NCT03092453)
|
| Host Response |
|
|
| References |
NCIT_C162250: Autologous mDC3 Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162250]
NCT03092453: Dendritic Cell Vaccination in Patients With Advanced Melanoma [https://clinicaltrials.gov/study/NCT03092453]
|
|
